D'Ardes Damiano, Pontolillo Michela, Esposito Lucia, Masciarelli Mara, Boccatonda Andrea, Rossi Ilaria, Bucci Marco, Guagnano Maria Teresa, Ucciferri Claudio, Santilli Francesca, Di Nicola Marta, Falasca Katia, Vecchiet Jacopo, Schael Thomas, Cipollone Francesco
"Clinica Medica" Institute, Department of "Medicine and Science of Aging", "G. d'Annunzio" University, 66100 Chieti, Italy.
Azienda Sanitaria Locale no. 2 Abruzzo Lanciano-Vasto-Chieti, 66100 Chieti, Italy.
Microorganisms. 2020 Aug 31;8(9):1327. doi: 10.3390/microorganisms8091327.
The diffusion of SARS-CoV-2, starting from China in December 2019, has led to a pandemic, reaching Italy in February 2020. Previous studies in Asia have shown that the median duration of SARS-CoV-2 viral shedding was approximately 12-20 days. We considered a cohort of patients recovered from COVID-19 showing that the median disease duration between onset and end of COVID-19 symptoms was 27.5 days (interquartile range (IQR): 17.0-33.2) and that the median duration between onset of symptoms and microbiological healing, defined by two consecutive negative nasopharyngeal swabs, was 38 days (IQR: 31.7-50.2). A longer duration of COVID-19 with delayed clinical healing (symptom-free) occurred in patients presenting at admission a lower PaO/FiO ratio ( < 0.001), a more severe clinical presentation ( = 0.001) and a lower lymphocyte count ( = 0.035). Moreover, patients presenting at admission a lower PaO/FiO ratio and more severe disease showed longer viral shedding ( = 0.031 and = 0.032, respectively). In addition, patients treated with corticosteroids had delayed clinical healing ( = 0.013).
2019年12月从中国开始的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)传播引发了一场大流行,并于2020年2月蔓延至意大利。此前在亚洲进行的研究表明,SARS-CoV-2病毒脱落的中位持续时间约为12 - 20天。我们研究了一组从冠状病毒病(COVID-19)中康复的患者,结果显示COVID-19症状出现至结束的中位病程为27.5天(四分位间距(IQR):17.0 - 33.2),症状出现至微生物学治愈(定义为连续两次鼻咽拭子检测阴性)的中位持续时间为38天(IQR:31.7 - 50.2)。入院时动脉血氧分压/吸入氧分数值(PaO/FiO)较低(<0.001)、临床表现更严重(=0.001)以及淋巴细胞计数较低(=0.035)的患者,COVID-19病程更长且临床治愈延迟(无症状)。此外,入院时PaO/FiO比值较低且疾病更严重的患者病毒脱落时间更长(分别为=0.031和=0.032)。另外,接受皮质类固醇治疗的患者临床治愈延迟(=0.013)。